



[CLICK HERE FOR
PI AND AE REPORTING](#) >

SHARED RESULTS

SHARED RELIEF

DOSING INSTRUCTIONS

DUPIXENT IS INDICATED FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD) IN PATIENTS AGED 12 YEARS OR OLDER AND FOR SEVERE AD IN CHILDREN AGED 6-11 YEARS OLD, WHO ARE CANDIDATES FOR SYSTEMIC THERAPY¹


SUBCUTANEOUS INJECTION BY PRE-FILLED PEN OR PRE-FILLED SYRINGE

[CLICK HERE FOR
PI AND AE REPORTING](#)



➤ DUPIXENT can be self-injected or administered by a caregiver to adults or adolescents with moderate-to-severe AD via a pre-filled pen or syringe after appropriate training by a healthcare professional (HCP)¹

➤ Children (6–11 years old) with severe AD, can **ONLY** be administered DUPIXENT via a **pre-filled syringe** by a caregiver after appropriate training by a HCP¹



*The subsequent dose may be increased to 200 mg Q2W in patients with body weight of 15 kg to less than 60 kg based on physician's assessment.¹

AD, atopic dermatitis; HCP, healthcare professional; Q2W, once every two weeks; Q4W, once every four weeks.

HOW TO STORE DUPIXENT?

[CLICK HERE FOR
PI AND AE REPORTING](#)



- DUPIXENT should be stored in a refrigerator (2 °C to 8 °C)¹
- Do not freeze¹
- Keep at room temperature for 45 minutes for 300 mg and 30 minutes for 200 mg before injection¹
- DUPIXENT may be kept at room temperature, up to 25 °C for a maximum of 14 days before being discarded¹
- The pre-filled pen or syringe should not be exposed to heat or light; store in the original carton in order to protect from light¹

[LEARN MORE ABOUT THE DOSING OF DUPIXENT FOR ALL POPULATIONS](#)





[CLICK HERE FOR
PI AND AE REPORTING](#) 

SHARED RESULTS

SHARED RELIEF

» First and **only targeted immunomodulator to specifically inhibit IL-4 and IL-13 signalling**, key drivers of persistent underlying Type 2 inflammation^{1,2}

» **Improvements** with DUPIXENT compared to placebo at 16 weeks in **all populations** and **sustained in adults** at 52 weeks in:^{1,3-8}

- Lesion extent and severity
- Pruritus intensity
- Quality-of-life measures

» **Consistent safety profile** across children, adolescents and adults. **Safety profile** investigated in **children** and **adolescents** for one year and in **adults** for 3 years¹

- No routine laboratory monitoring required¹

IL, interleukin.

REFERENCES: **1.** DUPIXENT Summary of Product Characteristics. Available at: <https://www.medicines.org.uk/emc/product/8553/smpc>. Date accessed: January 2021. **2.** Gandhi NA, et al. *Nature Rev Drug Disc* 2016;15:35-50. **3.** Blauvelt A, et al. *Lancet* 2017;389:2287-2303. **4.** de Bruin-Weller M et al. Clinically Meaningful Responses in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab (Presentation) presented at the 27th European Academy of Dermatology and Venerology Congress, Paris, France, September 12-16 2018. **5.** Simpson EL, et al. *JAMA Dermatol*. 2020;156(1):44-56. **6.** Paller AS, et al. *Am J Clin Dermatol*. 2020;21:119-131. **7.** Paller AS, et al. Dupilumab Significantly Improves Atopic Dermatitis in Children Aged ≥6 to <12 years: Results From Phase 3 Trial (LIBERTY AD PEDS) (Presentation) presented at the virtual Revolutionizing Atopic Dermatitis Conference, Chicago, IL, USA, April 5th 2020. **8.** Sanoñi Data on File. MAT-GB-2005006 (v1.0).